TY  -  
T1  - Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors : Current Status and Future Directions 
SN  -  /  
UR  - http://hdl.handle.net/10138/212223 
T3  -  
A1  - Bauer, Sebastian; Joensuu, Heikki 
A2  -  
PB  -  
Y1  - 2015 
LA  - eng 
AB  - Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of multiple mutations that confer drug resistance. Sunitinib and regorafenib are approved as second- and third-line agents, respectively, for patients whose GIST does not respond to imatinib or who do not to... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - KIT TYROSINE KINASE; PHASE-II; C-KIT; HSP90 INHIBITOR; PROGNOSTIC-FACTORS; ADJUVANT IMATINIB; RANDOMIZED-TRIAL; DRUG-RESISTANCE; BRAF MUTATIONS; DOSE IMATINIB; 3122 Cancers; 317 Pharmacy 
N1  -   
PP  -  
ER  -